Home Blog Page 1625

Investment of Approx. USD 460,000 for the Development of a Prototype Mpox Detection Test with NIPRO, TBA, Japan Institute for Health Security and others

By
Advertorial Desk
-

TOKYO, Dec. 8, 2025 /PRNewswire/ — The Global Health Innovative Technology (GHIT) Fund announced today an investment of approximately JPY 70 million (USD 460,0001) for the development of a prototype detection test for mpox (formerly known as monkeypox2).

Mpox is a viral infectious disease that has been spreading in the Democratic Republic of the Congo (DRC) and across sub-Saharan Africa. According to a situation report by the World Health Organization (WHO), more than 170,000 cases of mpox were confirmed in 141 countries between January 2022 and October 20253. WHO also reported that surveillance data for the January-May 2024 period in DRC indicated that 62% of the fatalities occurred in children aged under 5 years, where the case fatality ratio in this age group ranged from approximately 7 to 9%4. Due to the sharp increase in cases, a Public Health Emergency of International Concern (PHEIC) was declared again in August 2024 against the widespread outbreak in the African region, following the declaration made in July 2022. Although the emergency declaration was lifted in September 2025, mpox cases continue to be reported in neighboring countries, and the risk of severe complications and re-emergence remains a concern 5.

Mpox is mainly classified into two strains/clades, and infection rates and disease severity vary depending on the type. Locally, diagnostic systems currently available for identifying the clades remain insufficient, and developing simple and rapid diagnostic tests with clade distinguishing capabilities is urgently needed to prevent the further spread of infection.

Against this background, the GHIT Fund will invest approximately 70 million yen (USD 460,0001) in the development of a prototype mpox detection test. The project involves NIPRO CORPORATION, a global comprehensive healthcare company in the medical devices and pharmaceuticals; TBA Co., Ltd, a venture company originating from Tohoku University; the Japan Institute for Health Security (JIHS); the international non-profit organization PATH (USA); and the Institut National de Recherche Biomédicale (INRB). The project seeks to develop a prototype detection test capable of distinguishing clades using the Iso-PAS method—an inexpensive and simple genetic testing technique—and its performance will be evaluated. This will enable easy testing even in facilities with limited infrastructure, facilitating prompt and appropriate treatment while helping to prevent the spread of infection.

The GHIT Fund joined the Global Research Collaboration for Infectious Disease Preparedness (GloPID-R) 6 as a member in September 2025. GloPID-R brings together funders investing in research related to new or re-emerging infectious diseases. The GHIT Fund is the second organization from Japan to join GloPID-R as a member after the Japan Agency for Medical Research and Development (AMED). We will continue to support the development of innovative diagnostic technologies to enable swift responses to future public health challenges.

1 USD1 = JPY154.10, the approximate exchange rate on October 31, 2025.
2 Mpox was renamed from monkeypox by WHO in 2022
https://www.who.int/news/item/28-11-2022-who-recommends-new-name-for-monkeypox-disease
3 WHO: Global Mpox Trends. https://worldhealthorg.shinyapps.io/mpx_global/ (Published on November 21, 2025)
4 WHO: Disease Outbreak News Mox – Democratic Republic of the Congo https://www.who.int/emergencies/disease-outbreak-news/item/2024-DON522 (Published on June 21, 2024)
5 Africa CDC: https://africacdc.org/news-item/mpox-still-a-continental-emergency-africa-cdc-advisory-group-recommends/
(Published on September 4)
6 GloPID-R Secretariat receives funding from the European Union’s Horizon Europe research and innovation program.

The GHIT Fund is a Japan-based international public-private partnership (PPP) fund that was formed between the Government of Japan, multiple pharmaceutical companies, the Gates Foundation, Wellcome, and the United Nations Development Programme (UNDP). The GHIT Fund invests in and manages an R&D portfolio of development partnerships aimed at addressing neglected diseases, such as malaria, tuberculosis, and neglected tropical diseases, which afflict the world’s vulnerable and underserved populations. In collaboration with global partners, the GHIT Fund mobilizes Japanese industry, academia, and research institutes to create new drugs, vaccines, and diagnostics for malaria, tuberculosis, and neglected tropical diseases.
https://www.ghitfund.org/en

Appendix: Project Details

ID: G2025-125

Project Title

Development and performance evaluation of Iso-PAS technology for mpox detection (Iso-PAS Mpox)

Collaboration

Partners

1. NIPRO CORPORATION (Japan)

2. TBA Co., Ltd. (Japan)

3. Japan Institute for Health Security (JIHS/ Japan)

4. PATH (USA)

5. Institut National de Recherche Biomédicale
(INRB/ Democratic Republic of the Congo)

Disease

Mpox

Intervention

Diagnostic

Stage

Technical Feasibility

Awarded Amount

JPY 71,279,693 (USD 462,555)

Status

New Project

Summary

[Project objective]

A test kit will be developed that can distinguish between MPXV Clade I and Clade II using the Iso-PAS method, an inexpensive and simple genetic testing method. A future aim is to register the test kit on the WHO Emergency Use Listing (EUL) following the accumulation of proven data from MPXV outbreak regions.

[Project design]

The following activities are to be implemented in the project:

1) Development of a prototype Iso-PAS Mpox test kit, and its performance evaluation.

2) Performance study of the prototype kit using clinical specimens from the DRC.

Project Detail

https://www.ghitfund.org/investment/portfoliodetail/detail/250/en

*All amounts are listed at an exchange rate of USD1 = JPY154.10, the approximate exchange rate on October 31, 2025.

To learn more about the GHIT Fund’s investments, please visit
Investment Overview: https://www.ghitfund.org/investment/overview/en
Portfolio: https://www.ghitfund.org/investment/portfolio/en
Advancing Portfolio: https://www.ghitfund.org/investment/advancingportfolio/en
Clinical Candidates: https://www.ghitfund.org/investment/clinicalcandidates/en

For more information, contact:
Nancy Moss at +1-908-606-8940 or nmoss@burness.com
Mina Ohata at +81-36441-2032 or mina.ohata@ghitfund.org

Dulwich College Ranjit Murugason Sustainability Fund Secures Renewed Support from LGT Bank Singapore to Advance Student-Led Initiatives

By
Advertorial Desk
-

SINGAPORE, Dec. 8, 2025 /PRNewswire/ — The Dulwich College Ranjit Murugason Sustainability Fund is pleased to announce renewed support from LGT Bank Singapore (“LGT”), reinforcing a three-year collaboration that has helped Dulwich College (Singapore) students develop the skills, confidence and guidance needed to deliver meaningful sustainability and community projects across Singapore and the region.

The Sustainability Fund sits at the heart of the College’s Live Worldwise vision and Guiding Statements, encouraging students to take purposeful action and thoughtfully engage with issues of intercultural awareness, wellbeing, environmental sustainability and social justice.

LGT will be contributing a total of S$50,000 to the Fund—S$30,000 previously committed and a further S$20,000 in new support (S$10,000 in 2026 and S$10,000 in 2027). This ongoing partnership strengthens the Fund’s capacity to back a broader range of student initiatives and create more opportunities for young people to design and deliver impactful projects.

LGT became co-sponsor of the Sustainability Fund in 2022, partnering with Mr Ranjit Murugason to champion student initiatives addressing social and environmental challenges through research, collaboration and practical action. Their involvement has included both financial support and direct engagement. Mr Raveen Bharvani, Managing Director at LGT Bank Singapore and lead of the bank’s Employee Sustainability Group (ESG), has served annually as a judge for the College’s Call to Action Awards, providing mentorship and expert insight as students develop and present their proposals.

“Live Worldwise calls on our students to take meaningful action in the world, and the Sustainability Fund is one of the clearest expressions of that vision,” said Mr David Ingram, Head of Dulwich College (Singapore). “It offers authentic opportunities for students to lead, collaborate and see the real-world impact of their decisions. LGT’s support deepens our ability to provide these experiences, enabling more young people to engage confidently with complex challenges and make constructive contributions to their communities. We are deeply appreciative of their renewed partnership.”

“I am pleased to reaffirm LGT’s continued support for the Sustainability Fund,” said Mr Ranjit Murugason, Fellow of the College and founder of the Sustainability Fund. “Their renewed commitment reinforces the long-term foundation of the Fund and ensures we can continue investing in student initiatives with clarity, purpose and real impact. Since 2022, LGT has been a trusted partner whose belief in the potential of young people has broadened the scope and ambition of our work. I look forward to seeing this partnership support even more meaningful projects in the years ahead.”

“At LGT, we are committed to supporting initiatives that create positive impact and lasting value for our communities. Our continued collaboration with the Sustainability Fund reflects our dedication to fostering innovation, sustainability and social responsibility among future generations—reflecting the Princely Family of Liechtenstein’s legacy of responsible stewardship. We are pleased to stand alongside Dulwich College (Singapore) and its students as they transform bold ideas into real-world impact,” said Mr Adrian Baumgartner, CEO of LGT Bank Singapore.

Mr Raveen Bharvani, lead of the ESG Group at LGT Bank Singapore, said, “Over the past three years, we have been consistently impressed by the strategic thinking and leadership shown by Dulwich College (Singapore) students. Serving on the Call to Action Awards judging panel has offered a clear view of the calibre and creativity of these young people. We are excited to continue this partnership and contribute to the development of the next generation of responsible leaders.”

About Dulwich College (Singapore)

Dulwich College (Singapore) is a leading international school for students aged 2 to 18, drawing on over 400 years of heritage from Dulwich College in London and rooted in the ethos of the British independent school tradition. Guided by its vision to Live Worldwise and its Guiding Statements — Innovative Learning, Intercultural Awareness, Wellbeing, Diversity, Equity & Inclusion, Environmental Sustainability, and Social Justice — the College prepares students to make a positive difference in the world. Its rich curriculum balances academic excellence with holistic development in the arts, sport, innovation, and service, nurturing curious, compassionate global citizens.

For more information, visit singapore.dulwich.org

About LGT

LGT is a leading international private banking and asset management group that has been fully controlled by the Liechtenstein Princely Family for over 90 years. As at 30 June 2025, LGT managed assets of CHF 359.6 billion (USD 451.6 billion) for wealthy private individuals and institutional clients. LGT employs over 6000 people who work out of more than 40 locations in Europe, Asia, the Americas, Australia and the Middle East. www.lgt.com 

About the Dulwich College Ranjit Murugason Sustainability Fund

The Dulwich College Ranjit Murugason Sustainability Fund was established in 2022 to empower students to design practical, purposeful, and community-driven solutions to tackle the social and environmental challenges of the day. A collaboration between Dulwich College (Singapore) and Ranjit Murugason, Fellow of the College, parent, and Old Alleynian, the Sustainability Fund embodies the College’s vision to Live Worldwise and nurtures compassionate global citizens ready to make a positive difference in the world.

Global Times: Mogao Caves’ mural paintings meet modern technology

By
Advertorial Desk
-

BEIJING, Dec. 8, 2025 /PRNewswire/ — The flying Apsaras dance across the heavens; caravan bells echo along ancient routes. Dunhuang, a pivotal hub on the ancient Silk Road, served as a crossroads where diverse civilizations converged, giving birth to the radiant splendor of the Mogao Caves. As a world-renowned treasure house of art and cultural heritage, it integrates architectural excellence, sculptural artistry, mural paintings and Buddhist culture, which embody profound historical depth, rich cultural significance, and breath-taking artistic grandeur.

To showcase the contemporary brilliance of the cultural heritage, this special issue presents voices from Dunhuang’s guardians, inheritors, and researchers. Through their stories, we highlight achievements in researching, excavating, interpreting, transmitting, and promoting Dunhuang’s culture in the hopes of sharing the Dunhuang Model of protection and inheritance of cultural heritages with the rest of the world.

“Dun” means grand, and “Huang” means prosperous. In the eyes of the ancients, Dunhuang was a magnificent and flourishing place. The Mogao Caves in Dunhuang, which date back to 366 AD, bore witness to the exchange and mutual learning of the diverse civilizations along the ancient Silk Road, making them carriers of the wisdom of the Chinese nation. In this role, they have inspired admiration and fascination in countless scholars and artists from both China and abroad.

Carrying the weight of its long history, ancient Dunhuang now presents itself to the world with a renewed and graceful presence, resonating widely and profoundly in the modern era.

Digital rebirth

Facing the erosion of time, how can ancient grottoes retain their vitality? The Dunhuang Academy has provided an answer through its pioneering efforts. By leveraging digital and information technology, the Mogao Caves have been granted a “digital life,” enabling permanent preservation.

After decades of exploration, the Dunhuang Academy launched the “Digital Dunhuang” resource library in 2016, followed by an English version in 2017. The platform provides global access to high-definition images of murals and panoramic virtual tours of 30 caves. To date, the library has recorded over 23 million visits from users across 78 countries and regions. Digitalization has not only alleviated the tension between heritage preservation and tourism, but also facilitated broader global sharing of Dunhuang’s cultural and artistic resources.

In the digital realm, Dunhuang is not only visible but also interactive. Launched in 2023, the “Digital Cave of Manuscripts” uses modern technology to replicate the physical cave and its artifacts. At the tap of a finger, users can “travel” across different historical periods, immersing themselves in Dunhuang’s cultural experiences.

The Dunhuang Academy has helped World Heritage sites around the world and in China. Its focus on the caves and related preservation, its research, education and outreach, and also very importantly, links with other nations have helped it promote cooperation, said Shahbaz Khan, director of the UNESCO Regional Office for East Asia.

Interpretation of tradition

Known as a nation renowned for its refined attire and ceremonial dress, China has long emphasized the beauty of clothing and ornamentation. The exquisite murals and painted sculptures of the Dunhuang Mogao Caves embody dialogues and convergences of diverse civilizations in the art of attire, offering inspiration for contemporary fashion design.

“Dunhuang serves as a bridge connecting tradition and modernity,” said Zhang Baohua, a professor at the Academy of Art & Design, Tsinghua University, who is devoted to exploring ways to integrate traditional Chinese culture with modern art and design.

While preserving the distinctive features of Dunhuang elements, he employs modern design principles to deconstruct and reassemble them, ensuring the works retain their classical essence while meeting contemporary aesthetic demands.

“We need to preserve the essence of fine traditional culture while innovating its contemporary expression,” Zhang said.

Harmony with modern civilization

The Nine-Colored Deer, flying apsaras, caisson ceiling patterns… In recent years, an increasing number of Dunhuang cultural elements are integrated into daily life through illustrations, cultural and creative products, performances, and more.

“Dunhuang boasts a wealth of intellectual property (IP) resources. The key lies in how to ‘discover’ them,” said Zhao Xiaoxing, a professor at the Institute of Cultural Heritage of Northwestern Polytechnical University, who once worked at the Dunhuang Academy for a decade. In her view, developing cultural and creative products first requires a deep understanding of Dunhuang culture, while second comes a creative spark that enables one to innovatively express and “recreate” Dunhuang elements in ways that resonate with the public.

“Dunhuang belongs to history, yet it also lives in the present,” Zhao said. The murals of Dunhuang vividly capture diverse facets of life – from harvesting wheat and winnowing grain, to swimming and playing, traversing mountain paths, and enjoying outings in nature.

As the fluttering ribbons of celestial apsaras glide across mobile screens and ancient patterns adorn living spaces, Dunhuang – this radiant jewel in the desert – continues to shine with a vitality that transcends time and space.

“In 1943, at the age of 12, I followed my father Chang Shuhong to Dunhuang. In the years that followed, I joined the adults in copying murals inside the caves.”

Chang Shana
Former president of the Central Academy of Arts and Design

“The Dunhuang Caves are a cultural heritage of humanity. Through the study and dissemination of Dunhuang culture, we aim to promote cultural cooperation and exchange in today’s world.”

Zhao Shengliang
Distinguished professor at Northwest Normal University and a researcher at the Dunhuang Academy

“The Radiance of Dunhuang: Academy of Arts & Design, Tsinghua University Exhibition on Dunhuang Art and Design Achievements Special Presentation at the United Nations Headquarters will open on Monday.”

Li Yingjun
Deputy dean of the Academy of Arts & Design, Tsinghua University

CARsgen Announces Data of Allogeneic BCMA CAR-T Cell Therapy CT0596 for Relapsed/Refractory Multiple Myeloma at the 2025 ASH Annual Meeting

By
Advertorial Desk
-

SHANGHAI, Dec. 8, 2025 /PRNewswire/ — CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced that clinical data from its allogeneic BCMA-targeted CAR T-cell product candidate, CT0596, for the treatment of relapsed/refractory multiple myeloma (R/R MM) was presented in a poster at the 67th American Society of Hematology5 achieved PR or better. Six patients  (ASH) Annual Meeting. The poster was titled “A First-in-Human Study of CT0596, an Allogeneic CAR T-Cell Therapy Targeting BCMA, in Patients with Relapsed/Refractory Multiple Myeloma.” The publication number was 2296.

This clinical trial (NCT06718270) enrolled 8 patients with R/R MM in the dose-escalation phase who received CT0596 infusion. The median number of prior lines of therapy was 4.5 (range: 3-9). Enrollment was not restricted by NKG2A expression levels. Regarding lymphodepletion, 6 patients received full-dose lymphodepletion with fludarabine (30 mg/m²/day) and cyclophosphamide (500 mg/m²/day) for 3 consecutive days, while 2 patients received reduced-dose lymphodepletion. CT0596 was administered at dose levels of 1.5×10⁸ (n=1), 3×10⁸ (n=5), and 4.5×10⁸ CAR-T cells (n=2), with one patient receiving two infusions.

As of August 31, 2025, all 8 infused patients were evaluable for efficacy, with a median follow-up of 4.14 months (range: 0.9-7.9 months). Six patients achieved a partial response (PR) or better: 3 achieved complete response/stringent complete response (CR/sCR) (all in the full-dose lymphodepletion group), 1 achieved very good partial response (VGPR), and 2 achieved PR. Among the 6 patients who received full-dose lymphodepletion, 5 achieved PR or better. Six patients  in the full-dose lymphodepletion group achieved minimal residual disease (MRD)-negativity at Week 4. Patient 01 maintained ongoing sCR and MRD-negativity as of Month 8. Patient 04 achieved PR with resolution of extramedullary disease following the second infusion. CAR-T cell expansion was observed in all 8 patients. Among the two patients who received the 4.5×10⁸ dose, one achieved sCR, and the other exhibited deepening response to VGPR.

CT0596 demonstrated a manageable safety profile. Four patients experienced Grade 1 cytokine release syndrome (CRS); no Grade 2 or higher CRS was observed. No immune effector cell-associated neurotoxicity syndrome (ICANS) or graft-versus-host disease (GVHD) was reported. No dose-limiting toxicities, treatment discontinuations, or deaths were observed.

The study is still in the dose-exploration phase. The lymphodepletion regimen has been determined, and higher cell doses are being explored to further define the recommended dose (RD). The company plans to initiate a Phase 1b registrational study for CT0596 in 2026.

About CT0596

CT0596 is an allogeneic BCMA-targeted CAR-T therapy developed using CARsgen’s proprietary THANK-u Plus™ platform. It is currently being evaluated in investigator-initiated trials for relapsed/refractory multiple myeloma (R/R MM) or plasma cell leukemia (PCL). CT0596 demonstrated preliminary favorable tolerability and encouraging efficacy signals. Further investigation is planned in additional plasma cell malignancies and autoimmune diseases mediated by autoreactive plasma cells. The company anticipates submitting an Investigational New Drug (IND) application in the second half of 2025.

About CARsgen Therapeutics Holdings Limited

CARsgen is a biopharmaceutical company focusing on developing innovative CAR T-cell therapies to address the unmet clinical needs including but not limited to hematologic malignancies, solid tumors and autoimmune diseases. CARsgen has established end-to-end capabilities for CAR T-cell research and development covering target discovery, preclinical research, product clinical development, and commercial-scale production. CARsgen has developed novel in-house technologies and a product pipeline with global rights to address challenges faced by existing CAR T-cell therapies. Efforts include improving safety profile, enhancing the efficacy in treating solid tumors, and reducing treatment costs, etc. CARsgen’s mission is to be a global biopharmaceutical leader that provides innovative and differentiated cell therapies for patients worldwide and makes cancer and other diseases curable.

Forward-looking Statements

All statements in this press release that are not historical fact or that do not relate to present facts or current conditions are forward-looking statements. Such forward-looking statements express the Group’s current views, projections, beliefs and expectations with respect to future events as of the date of this press release. Such forward-looking statements are based on a number of assumptions and factors beyond the Group’s control. As a result, they are subject to significant risks and uncertainties, and actual events or results may differ materially from these forward-looking statements and the forward-looking events discussed in this press release might not occur. Such risks and uncertainties include, but are not limited to, those detailed under the heading “Principal Risks and Uncertainties” in our most recent annual report and interim report and other announcements and reports made available on our corporate website, https://www.carsgen.com. No representation or warranty is given as to the achievement or reasonableness of, and no reliance should be placed on, any projections, targets, estimates or forecasts contained in this press release.

RESPIREE SECURES SINGAPORE HSA APPROVAL FOR ITS AI-ENABLED 1BIO™AI SOFTWARE TO SUPPORT ACUTE DETERIORATION DETECTION

By
Advertorial Desk
-

SINGAPORE, Dec. 8, 2025 /PRNewswire/ — AI/ML health-tech startup Respiree has received approval from the Health Sciences Authority (HSA) for its 1Bio™AI-Acute toolbox as a Class B software-as-a-medical device (SaMD). The solution is designed to support healthcare professionals in identifying acute inpatient deterioration using AI-enabled machine learning models. Compared to the current standard of care, 1Bio™AI-Acute delivers significantly higher precision in acute deterioration notifications, resulting in fewer false alerts and more efficient clinical support.

Illustrative Marketing logo for 1Bio™AI
Illustrative Marketing logo for 1Bio™AI

The 1Bio™AI-Acute system uses only bedside-recorded vital signs—pulse rate, respiratory rate, oxygen saturation, and systolic blood pressure—to generate a probability score that assists clinicians in determining whether additional monitoring may be required. This score provides an indication of the patient’s general physiological state: the higher the score, the greater the likelihood that the patient may require additional monitoring due to potential acute deterioration.

WHY IT MATTERS

“Current early-warning scores that rely on threshold-based methods often suffer from low precision, leading to a high number of alarms and notifications. Advanced AI-driven machine learning models have the potential to deliver significantly greater precision, reducing unnecessary alerts/notifications, thus enabling healthcare professionals to better focus their time on delivering quality patient care,” said Dr. Gurpreet Singh, CEO and Founder of Respiree.

The 1Bio™AI-Acute is readily available to healthcare professionals through Respiree’s 1Bio™ platform, which recently received regulatory clearance together with the RS001 wearable device. With this milestone, the 1Bio™AI-Acute toolbox, the 1Bio™platform, and the RS001 wearable are all now approved by HSA.

With the HSA approval for the 1Bio™AI-Acute toolbox, Respiree is now setting its sights on expanding the 1Bio™AI-Acute regulatory approvals across other APAC and ANZ regions, as well as in the United States, in the coming months.

HSA’s approval of the 1Bio™AI-Acute toolbox follows the validation study that was recently peer-reviewed and published in the Mayo Clinic Proceedings.

About Respiree

Respiree™ is an AI/ML health tech company building clinically-validated AI for managing disease progression. Respiree™ products are CE marked and has received regulatory clearances from the Therapeutic Goods Administration and the United States Food and Drug Administration (FDA).

AI-for-Science Startup ChemLex Raises USD 45M, Launching Self-Driving Lab for Drug Discovery in Singapore

By
Advertorial Desk
-

SINGAPORE, Dec. 8, 2025 /PRNewswire/ — ChemLex, a next-generation AI-for-science company, today announced the establishment of its global headquarters and self-driving laboratory in Singapore, alongside the close of a USD 45 million funding round led by Granite Asia. 

Founded in 2022, ChemLex develops AI technologies that radically accelerate chemical discovery for the pharmaceutical industry, significantly reducing time-to-market. In just three and a half years, it has grown to support more than 70 customers worldwide, including six of the world’s top ten pharmaceutical companies. This surge reflects a larger industry shift as analysts expect the AI-powered drug discovery market to jump from USD 3.6B in 2024 to nearly USD 50B by 2034. 

At the core of ChemLex’s platform is a 24/7 autonomous chemistry system that accelerates chemical discovery, making it far more cost-efficient and significantly more sustainable than traditional laboratory methods. Driving this is an innovative AI-powered, fully automated synthesis line, which runs experiments autonomously, captures data in real-time, and transforms chemical discovery from a stop-start process into a smooth workflow.

The new funding will support the hiring of more hardware and software engineers, as well as chemists in Singapore, enabling the company to serve a broader pipeline of pharmaceutical and materials science projects. 

Sean Lin, Founder and CEO of ChemLex: “We’re building an R&D engine that compresses months of synthesis and optimisation into weeks or even days, transforming both the speed and certainty of discovery. Singapore strengthens this effort and provides us an ecosystem to scale rapidly and support partners globally who need this capability now.”

Yinghui Kuang, Partner at Granite Asia: “AI-enabled chemistry is creating one of the most important industrial transitions of the decade, and ChemLex sits in that sweet spot, turning that shift into a business advantage with a platform that can accelerate molecule design and manufacturing at scale. This is the type of deeptech company that can reshape supply chains, shorten development timelines, and unlock new economic value, and Singapore gives them the foundation to grow.”

ChemLex also signed a memorandum of understanding with the Experimental Drug Development Centre (EDDC), Singapore’s national platform for drug discovery and development. This collaboration seeks to accelerate next-generation small molecule drug discovery through advanced automation.

Prof. Damian O’Connell of the Experimental Drug Development Centre: “We first met ChemLex in 2023, and since then we’ve seen the company grow from a promising startup to a global innovator in AI and automation-driven chemical synthesis. As ChemLex’s first Singapore partner, we are thrilled to expand our collaboration through the MOU. This partnership reinforces our shared vision of accelerating drug discovery and development through cutting-edge technology, ultimately bringing safer, more effective therapies to patients faster. By combining EDDC’s drug development expertise with ChemLex’s automation and AI capabilities, we aim to shorten timelines, reduce costs, and deliver innovative treatments that improve lives in Singapore and globally.”

These initiatives align with the Singapore Economic Development Board’s (EDB) efforts to build a more resilient, innovation-ready life sciences ecosystem.

Goh Wan Yee, Senior Vice President and Head, Healthcare, Economic Development Board: “ChemLex’s decision to anchor its global R&D headquarters and AI laboratory in Singapore reflects how companies can leverage the confluence of our strengths in deep tech and biomedical sciences ecosystem, to launch breakthrough innovations. We look forward to supporting more like-minded partners like ChemLex, to accelerate scientific discoveries that will benefit patients worldwide.”

ProstACT Global Phase 3 Update: First Patient Dosed in Randomized Treatment Expansion, Part 1 Readout Plans Confirmed

By
Advertorial Desk
-

MELBOURNE, Australia and INDIANAPOLIS, Dec. 8, 2025 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the first patient has been dosed in Part 2 (randomized treatment expansion) of its ProstACT Global Phase 3 study evaluating its lead prostate cancer therapy candidate TLX591 (lutetium (177Lu) rosopatamab tetraxetan) in patients with metastatic castration resistant prostate cancer (mCRPC). The patient was dosed at the Australian Prostate Centre (APC) in Melbourne, Australia.

ProstACT Global is the first Phase 3 trial to combine a PSMA[1]-targeted radio antibody-drug conjugate (rADC) therapy administered together with Standard of Care (SOC; abiraterone, enzalutamide or docetaxel) versus SOC alone. Part 2 of ProstACT Global will enroll approximately 490 patients and is currently recruiting patients in Australia, New Zealand and Canada.

As previously agreed with FDA and disclosed to the market, Telix will submit Part 1 data to the United States (U.S.) Food and Drug Administration (FDA) to enable clearance to expand Part 2 of the trial to U.S. sites. A public disclosure of preliminary results from Part 1 of the study will be aligned to engagement with the FDA.

The study is also approved to commence in China, Japan[2], Singapore, South Korea, Türkiye and the United Kingdom. As part of the further global expansion of the trial, Telix will file a clinical trial application (CTA) with the European Medicines Agency (EMA) to enable expansion into EU sites.

Dr. David N. Cade, Group Chief Medical Officer, Telix, commented, “Dosing the first patient into Part 2 of the randomized treatment expansion of ProstACT Global trial is a significant milestone for Telix’s late-stage prostate cancer therapeutics pipeline. We look forward to presenting the preliminary data from Part 1 of the study to the FDA and EMA in the coming months[3].”

About ProstACT Global

ProstACT Global (ClinicalTrials.gov ID: NCT06520345) is an international, multicenter trial in two parts: Part 1, safety and dosimetry lead-in with 30 patients (target enrollment complete); and Part 2, 2:1 randomized global expansion with an overall target enrollment of approximately 490 patients. Eligible patients must have confirmed progressive mCRPC assessed with a 68Ga-PSMA-11 PET[4] imaging agent (such as Illuccix® or Gozellix®, kits for the preparation of gallium-68 (68Ga) gozetotide injection) following prior treatment with an androgen receptor pathway inhibitor (ARPI).

The antibody approach demonstrates different targeting and pharmacology to that observed in other PSMA-targeted small peptide radioligand therapies (RLT). In contrast to these therapies[5], collective long-term follow-up of patients administered with TLX591 has not observed significant acute or delayed kidney toxicity, as the agent is cleared through the liver, instead of the kidneys[6]. Due to its large molecular weight, TLX591 also demonstrates minimal salivary and lacrimal gland uptake, reducing dry mouth and dry eyes, common adverse effects of existing PSMA-targeted RLTs[7].

Additional information on the Phase 3 ProstACT Global study can be found at: 

https://telixpharma.com/prostact/ 

About Telix Pharmaceuticals Limited

Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, United Kingdom, Brazil, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).

Illuccix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection), Telix’s first generation PSMA-PET imaging agent, has been approved in multiple markets globally. Gozellix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection) has been approved by the U.S. FDA[8]. TLX591 has not received a marketing authorization in any jurisdiction.

Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and U.S. Securities and Exchange Commission (SEC) filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook.

[1] Prostate-specific membrane antigen.

[2] Japanese regulator Pharmaceuticals and Medical Devices Agency (PMDA) has granted approval for a Japan-specific Part 1 in nine patients, prior to commencing Part 2.

[3] Collation of available published data. Not from head-to-head studies, cross trial or product data should be interpreted with caution.

[4] Positron emission tomography.

[5] Tagawa et al. Curr Oncol Rep. 2021; Steinhelfer et al. JNM. 2024.

[6] Tagawa et al. Cancer. 2019.

[7] Pepin et al. Pract Radiat Oncol. 2025.

[8] Telix ASX disclosure 21 March 2025.

 

Telix Investor Relations (Global)
Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Investor Relations and Corporate Communications
Email: kyahn.williamson@telixpharma.com

Telix Investor Relations (U.S.) 
Annie Kasparian 
Telix Pharmaceuticals Limited  
Director Investor Relations and Corporate Communications 
Email: annie.kasparian@telixpharma.com 

Media Contact
Eliza Schleifstein
917.763.8106 (Mobile)
Eliza@schleifsteinpr.com

This announcement has been authorized for release by the Telix Pharmaceuticals Limited Disclosure Committee on behalf of the Board.

Legal Notices

Cautionary Statement Regarding Forward-Looking Statements. 

You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification.  To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.

©2025 Telix Pharmaceuticals Limited. All rights reserved.

/C O R R E C T I O N — China International Supply Chain Expo/

By
Advertorial Desk
-

In the news release, “The 4th China International Supply Chain Expo Set for Beijing in June 2026“, issued on Dec.7, 2025 by China International Supply Chain Expo over PR Newswire, we are advised by the company that there should be two photos with photo captions rather than just 1 photo without photo caption, as originally issued inadvertently. Complete, corrected release follows:

The 4th China International Supply Chain Expo Set for Beijing in June 2026

Sustained Worldwide Outreach Drives Greater Collaboration Opportunities

BEIJING, Dec. 7, 2025 /PRNewswire/ — The 4th China International Supply Chain Expo (“CISCE,” “the Expo”) will be held in Beijing from June 22 to 26, 2026. To date, more than 300 companies have signed up to exhibit, with preparations moving forward smoothly.

From November 30 to December 2, a delegation of Chinese business leaders organized by the China Council for the Promotion of International Trade (CCPIT) visited Canada, engaging in broad exchanges with government and industry representatives. At the Canada-China Forum on Trade and Investment Cooperation, the group gave a presentation on the upcoming Expo to over 150 government officials, institutional leaders, and corporate executives from both countries. Discussions centered on deepening collaboration in advanced manufacturing, digital technology, clean energy, and sustainable agriculture.

Canada-China Forum on Trade and Investment Cooperation Held in Toronto，On-site Promotion the 4th China International Supply Chain Expo (CISCE).
Canada-China Forum on Trade and Investment Cooperation Held in Toronto，On-site Promotion the 4th China International Supply Chain Expo (CISCE).

Following this, the CCPIT dispatched a delegation to the United States, engaging in extensive dialogues with American political and business leaders while conducting multiple promotional events across the country. On December 4, in Washington, D.C., CCPIT President Ren Hongbin addressed the forum “From Policy to Partnership: APEC 2026 – Unlocking Trade and Investment Potential.” He noted the reciprocal benefits of U.S.-China commercial relations while reaffirming CCPIT’s role in deepening practical cooperation and promoting the steady and long-term development of bilateral economic and trade ties. U.S. attendees showed considerable interest in strengthening supply chain ties with China. During the forum, the China International Exhibition Center Group delivered a dedicated presentation on the 4th CISCE.

The Forum “From Policy to Partnership: APEC 2026 – Unlocking Trade and Investment Potential” Held in Washington, D.C. On-site Promotion the 4th China International Supply Chain Expo (CISCE)
The Forum “From Policy to Partnership: APEC 2026 – Unlocking Trade and Investment Potential” Held in Washington, D.C. On-site Promotion the 4th China International Supply Chain Expo (CISCE)

On December 5, the delegation attended the “Port of Opportunity: U.S.-China Business Networking Breakfast” in Oakland, California, focusing on digital technology, artificial intelligence, and other emerging sectors, to explore joint innovation opportunities within the two countries’ industrial ecosystems. Another detailed presentation on the 4th CISCE was also shared.

The Expo has become a vital platform for advancing international cooperation in global industrial and supply chains. The China Council for the Promotion of International Trade stated that it will continue to adhere to the strategic guidance of the 15th Five-Year Plan, ensuring high standards and superior quality in all preparations for the fourth edition of the Expo.

Please visit https://en.cisce.org.cn/ for more up-to-date news about the 4th China International Supply Chain Expo.

 

1...1,6241,6251,626...6,508Page 1,625 of 6,508